On April 25, 2025, Cuu Long Pharmaceutical Joint Stock Company (Stock Code: DCL) successfully held its 2025 Annual General Meeting of Shareholders (AGM) in an online format.
During the meeting, the AGM listened to and approved the 2024 performance reports from the Board of Directors, Executive Board, and Supervisory Board. It also reviewed and provided input on the 2025 business plan. Shareholders approved several proposals, including the 2025 business plan, the standalone and consolidated audited financial statements for 2024, the selection of the auditing firm for 2025, and other matters within the AGM’s authority.
In 2024, the pharmaceutical industry continued to face numerous challenges. In response, DCL focused on evaluating and forecasting business conditions to formulate strategic solutions for managing operations effectively. Backed by the strategic vision of F.I.T Group, effective investment project management, and the development of a nationwide distribution network, DCL maintained operational stability and achieved 95% of its revenue target as approved at the 2024 AGM. According to the audited 2024 consolidated financial statements, DCL’s total assets increased from VND 2,277 billion to over VND 2,424 billion, and shareholder equity rose from VND 1,450 billion to over VND 1,503 billion.
2024 also marked a year of recognition for DCL, as the company was honored with multiple prestigious awards, including: Top 20 Sustainable Development Enterprises and Top 50 Strong ASEAN Brands.
At the meeting, the AGM approved the resignation and election of new members to the Supervisory Board for the 2022–2027 term. Following an open voting process, Ms. Ngo Thu Trang and Ms. Le Thi Thuong were elected as new members of the Supervisory Board.
The AGM conducted an open vote to elect new members to the Supervisory Board.
Also during the session, shareholders approved the 2025 Business Plan, which outlines key performance indicators and strategic priorities.
The Board of Directors will intensify its guidance to the Executive Board, focusing on the company’s core operational areas and adopting flexible management strategies aligned with market conditions:
-
Pharmaceutical Sector: In 2024, DCL launched a project to upgrade its Nonbetalactam Plant in Vinh Long to meet EU-GMP standards, with completion expected in 2025. This will support export expansion and improve revenue and profitability. Additionally, in Q2/2025, the company will break ground on a new EU-GMP-compliant pharmaceutical manufacturing facility in Long An. The project covers a total area of 50,000 square meters, divided into two phases: Phase 1 will build a plant for cancer drug production, and Phase 2 will construct high-tech biological drug facilities, plant-based capsule production lines, a central warehouse, and a cosmetics and personal care manufacturing plant.
-
Medical Equipment Sector: In March 2025, Benovas Medical Equipment JSC inaugurated a new factory capable of producing 21.5 million units per month. This facility not only meets domestic demand but also meets quality standards for exports to Europe and the U.S. In response to increasing demand for medical devices, the factory is committed to stable product supply and plans to invest in new equipment to produce additional items such as test tubes, IV catheters, butterfly needles, and dialysis filters.
-
Empty Capsule Production: The Vicancap manufacturing facility, equipped with advanced Canadian technology, is currently operating at full capacity to meet domestic and international orders. With rising demand for empty capsules in the pharmaceutical and functional food industries, DCL completed Phase 5 of its expansion with a VND 232.5 billion investment, increasing capacity by 2.8 billion capsules/year—raising total capacity to 11.6 billion capsules/year. In 2024, the company also obtained FDA certification for its hard gelatin capsule products manufactured at the Capsule Plant.
With a spirit of unity, responsibility, and innovation, the 2025 AGM concluded successfully, reaffirming the strong connection between company leadership and shareholders on the path to sustainable development. The strategic directions approved at the meeting not only serve as a roadmap for 2025 business operations but also reflect DCL’s ambition to rise as a prominent player in Vietnam’s and the region’s pharmaceutical and healthcare landscape. With a solid foundation, Cuu Long Pharmaceutical is confident in entering a new phase—more efficient, more innovative, and poised for breakthrough growth.
